LLY

1,128.7

+0.06%↑

JNJ

235.06

-0.36%↓

ABBV

221.75

-0.19%↓

UNH

410.63

-0.37%↓

MRK

115.08

-0.21%↓

LLY

1,128.7

+0.06%↑

JNJ

235.06

-0.36%↓

ABBV

221.75

-0.19%↓

UNH

410.63

-0.37%↓

MRK

115.08

-0.21%↓

LLY

1,128.7

+0.06%↑

JNJ

235.06

-0.36%↓

ABBV

221.75

-0.19%↓

UNH

410.63

-0.37%↓

MRK

115.08

-0.21%↓

LLY

1,128.7

+0.06%↑

JNJ

235.06

-0.36%↓

ABBV

221.75

-0.19%↓

UNH

410.63

-0.37%↓

MRK

115.08

-0.21%↓

LLY

1,128.7

+0.06%↑

JNJ

235.06

-0.36%↓

ABBV

221.75

-0.19%↓

UNH

410.63

-0.37%↓

MRK

115.08

-0.21%↓

Search

Coherus Oncology Inc

Avatud

SektorTervishoid

1.36 -2.86

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.33

Max

1.3900000000000001

Põhinäitajad

By Trading Economics

Sissetulek

-278M

-37M

Müük

-438K

12M

P/E

Sektori keskmine

3.509

49.052

Aktsiakasum

-0.25

Kasumimarginaal

-300.041

Töötajad

145

EBITDA

7.9M

-35M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+506.62% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

6. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-40M

219M

Eelmine avamishind

4.22

Eelmine sulgemishind

1.36

Uudiste sentiment

By Acuity

50%

50%

162 / 342 Pingereas Healthcare

Coherus Oncology Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Ettevõttest Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
help-icon Live chat